Allergic disease in children: integrated approach: Viva

Branch 1: Recognising the integrated problem

The candidate should recognise immediately that this is not three separate diseases but one atopic tendency expressed across skin, gut and airway. The severe early-onset eczema, the immediate reaction to egg, and the new nocturnal wheeze are the atopic march unfolding in real time, and the family atopy history confirms the genetic substrate. The single organising idea is to treat the whole child, not the presenting organ. [4]

The first priorities are to classify each manifestation by mechanism, to confirm the food allergy properly rather than on testing alone, to assess the severity and control of each organ, and to build one coordinated plan. The candidate should articulate a one-sentence problem representation: a three-year-old with multisystem atopic disease (eczema, IgE-mediated egg allergy, early asthma) following the atopic march, requiring an integrated plan and an adrenaline autoinjector pending clarification of the food allergy. [3]

Branch 2: Classification and the atopic march

The examiner will ask the candidate to classify the diseases by mechanism and to explain the march. The eczema is a non-IgE / mixed Th2-and-barrier disease; the immediate urticaria and wheeze after egg is an IgE-mediated reaction that may have been anaphylaxis and must be clarified by history; and the nocturnal cough and wheeze is early asthma, a chronic type-2 lower-airway disease. The mechanism matters because it determines the adrenaline decision: only the IgE-mediated food allergy warrants an autoinjector. [3]

The atopic march is the sequence of eczema and food allergy in infancy followed by rhinitis and asthma in the pre-school years, driven by shared type-2 biology. Barrier breakdown allows transcutaneous sensitisation, interleukin-4 and interleukin-13 drive immunoglobulin E class switching, and interleukin-5 sustains eosinophilia. Early-onset severe eczema is the strongest predictor of progression, which is why aggressive skin control is prevention, not just symptom relief. [4]

Branch 3: The food allergy and the adrenaline decision

The examiner will probe whether this child's egg reaction was anaphylaxis and whether she needs an autoinjector. Anaphylaxis is a clinical diagnosis of rapid airway, breathing or circulation compromise with skin change after a trigger; the immediate wheeze after egg meets this if the respiratory component was significant, and the worst-ever reaction, not the most recent, drives the plan. A clear history of the reaction, supplemented by serum tryptase if available from the event, is the basis for the decision. [3]

The candidate should state that a positive skin-prick test or specific immunoglobulin E indicates sensitisation, not clinical allergy, and that the diagnosis rests on a compatible history plus a convincing reaction or a supervised oral food challenge. Egg allergy resolves in around half of children by two years and most by school age, so serial trends and a planned challenge are central, and the autoinjector is continued while any systemic IgE-mediated reactivity persists. [4]

Branch 4: Prevention and the skin-barrier nuance

The examiner will ask how the march could have been modified and what advice applies to a younger sibling. The LEAP trial showed that early peanut introduction from four to eleven months in high-risk infants reduced peanut allergy by around 80 per cent, and the NIAID addendum recommends peanut introduction from around four to six months with test-then-feed for the severe-eczema or egg-allergic infant. The same early-introduction principle applies to this child's siblings. [1][2]

The skin-barrier prevention story is more nuanced and is a common viva trap. The KEEP trial showed that neonatal emollient reduced eczema in a high-risk cohort, but the larger BEEP trial and its five-year follow-up found no overall prevention benefit from daily emollient from birth. The integrated conclusion is to treat established eczema aggressively but not to recommend universal neonatal emollient as prevention. The candidate who holds both trials together outperforms the one who cites only the positive study. [5][6]

Branch 5: The oral-immunotherapy question

The examiner will ask whether oral immunotherapy should be offered for this child's food allergy. The candidate should frame it as a shared decision rather than a default: agents such as AR101 desensitise a majority of peanut-allergic children, but the PACE meta-analysis confirmed a substantial burden of reactions and adrenaline use during treatment, so the trade-off is between the safety of strict avoidance with an autoinjector and the desensitisation-but-reaction-burden of active treatment. The decision turns on quality of life and adherence capacity, and the integrated answer is to optimise everything else first. [7]

The closing point is the one the examiner is listening for: the integrated allergic child is one child with one tendency, so the plan is one plan, with one lead clinician, one written action plan and regular review of the whole child. That single organising idea is the fellowship-level answer. [4]